BioPharm America™ 2014 Program Overviewwww.ebdgroup.com/bpa/program
|Sunday, September 21, 2014|
BioPharm America Welcome Reception
All BioPharm America attendees are cordially invited to join us for a welcome reception.
You will be able to pick up your name badge at the welcome reception.
|Tuesday, September 23, 2014|
Pharma and Large Biotech Presentations
8:30 am – Merck
|8:00 am–6:00 pm
One-to-one Meetings ►
|11:15 am–12:30 pm||Company Presentations ►|
Challenges in developing differentiated treatments for autoimmune diseases
Humira is currently the top selling pharmaceutical in the world and represents just one of eight approved targeted therapies for RA, a market with an estimated prevalence of less than USD 5 million in the seven major pharmaceutical markets. Rheumatoid arthritis, as well as many of the other indications in which anti-TNFs are entrenched, has all the hallmarks of a mature market (including biosimilars on the horizon), and many view the market as overcrowded. However, significant unmet medical needs remain in RA, where approximately one-third of patients are not achieving a 20% improvement in symptoms on biologics, and needs are even greater in other indications such as IBD. Within this setting, developers of early stage programs are struggling to differentiate their programs and to choose the appropriate indication and path forward for clinical development. Our panel will discuss the challenges associated with differentiating products at early stages of development in autoimmune disease, and potential strategies for choosing lead indications and demonstrating proof-of-relevance to potential partners and/or investors, as well as patients and payers.
|1:30–4:30 pm||Company Presentations ►|
The nearest exit may be behind you: The story of CoStim Pharmaceuticals
On February 17, 2014, CoStim Pharmaceuticals, a little startup just about a year removed from its first big funding round and focused on the hot field of immune checkpoint biology, was acquired by Novartis. In this session, the key players—co-founders, investors and Novartis—will share the company's story, from vision and formation through exit and beyond.
Harvard Innovation Exhibit and Reception
Hosted by:Harvard University
|Wednesday, September 24, 2014|
|8:30 am–12:30 pm||Company Presentations ►||8:00 am–3:00 pm
One-to-one Meetings ►
All innovation roads lead to Massachusetts: Pharma's approach to the Boston biotech cluster
Undoubtedly, Boston is one of the most fertile biotech breeding grounds in the world. Top research institutes, early stage VC money, the who-is-who in serial entrepreneurs and a solid representation of mature biotechs, all within a few square miles, create an unmatched environment for innovation to thrive. No wonder most pharma companies are building a strong presence to be close to the action. During this session the leaders of several Boston R&D centers will discuss their approach to accessing innovation.
Academic Innovators™ Showcase
Join us for our Academic Innovators™ presentation track as we work with industry leaders to shine a spotlight on the many scientific advances with strong translational potential being made in the academic world.